Results 201 to 210 of about 22,441 (303)

Safety and pharmacokinetics of mosliciguat, a new, inhaled soluble guanylate cyclase activator, in healthy adult subjects

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Mosliciguat (BAY 1237592), the first soluble guanylate cyclase (sGC) activator in a dry powder inhaler (DPI), could potentially treat pulmonary hypertension with a more targeted delivery than systemic sGC stimulators. We report safety and tolerability of mosliciguat in healthy men.
Johannes Nagelschmitz, Soundos Saleh, Sandra Ligges, Melanie Seidel‐Greven, Eva Becker‐Pelster, Sylvia M. Nikkho, Stefanie Boxnick, Wolfgang Timmer   +7 more
wiley   +1 more source

How do placebos work?

European Journal of Psychotraumatology, 2018
Fabrizio Benedetti, Alessandro Piedimonte, Elisa Frisaldi   +2 more
doaj   +1 more source

Dismantling open-label placebos and their rationales: A remote 4-arm randomized controlled trial protocol. [PDF]

Contemp Clin Trials
Druart L, Lay P, Baird GL, Beaudoin FL, Totten J, Sutherland J, Rosen R, Bernstein MH.   +7 more
europepmc   +1 more source

Placebos: Current Clinical Realities

, 2008
Sherman, Rachel, Hickner, John
core  

Development of a nalmefene formulation suitable for a community‐use auto‐injector

British Journal of Clinical Pharmacology, EarlyView.
Aim Time to onset of reversal is critical when treating opioid‐induced respiratory depression and hypoxia. This study aimed to develop a formulation of the opioid antagonist nalmefene with an increased absorption rate and reduced time to onset of reversal following intramuscular administration. Methods Several absorption enhancers were screened in rats,
Alessandra Cipriano, Manjunath S. Shet, Hugh Huang, Ronnie Ortiz, Garth T. Whiteside, Glen Apseloff, Stephen C. Harris   +6 more
wiley   +1 more source

ETVAX: From Concepts to Demonstrated Clinical Efficacy. [PDF]

Microorganisms
Svennerholm AM.
europepmc   +1 more source

Semaglutide vs. liraglutide and incidence of diabetes and cardiovascular disease: A target trial emulation using real‐world data

British Journal of Clinical Pharmacology, EarlyView.
Aims The glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) semaglutide and liraglutide are approved for chronic weight management. Both drugs also have favourable effects on the risk of developing diabetes and cardiovascular disease (CVD) compared with placebo, but their comparative effectiveness for these outcomes is unclear.
Ethan J. Cannon, Wendy Wang, Faye L. Norby, Rob F. Walker, Shalini Kulasingam, Lisa S. Chow, Joel F. Farley, Pamela L. Lutsey   +7 more
wiley   +1 more source

A dose of doubt: a qualitative study on placebo regulations. [PDF]

Front Med (Lausanne)
Richard M, Ganz M, Elger BS, Gaab J.
europepmc   +1 more source

Placebos and Suicide

, 2000

core  

Regulatory harmonization: Evolution, globalization and future directions

British Journal of Clinical Pharmacology, EarlyView.
Regulatory harmonization has become an increasingly important and accepted approach to streamline regulatory review processes and expedite access to safe, effective and high‐quality medicines globally. This review explores the evolution and current status of regulatory harmonization, convergence and reliance initiatives.
Orin Chisholm, Elaine Y. L. Blair, Christine Y. Lu   +2 more
wiley   +1 more source